Critical Reviews in Oncology Hematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Biomarkers in Prostate Cancer – Current Clinical Utility and Future Perspectives
Current tendencies in the treatment course of prostate cancer patients increase the need for reliable biomarkers that help in decision-making in a challenging clinical setting. Within the last decade, several novel biomarkers have been introduced. In the following comprehensive review article, we focus on diagnostic (PHI ®, 4K score, SelectMDx®, ConfirmMDx®, PCA3, MiPS, ExosomeDX, mpMRI) and prognostic (OncotypeDX GPS®, Prolaris®, ProMark®, DNA-ploidy, Decipher®) biomarkers that are in widespread clinical use and are supported by evidence. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - November 13, 2017 Category: Cancer & Oncology Authors: Alexander Kretschmer, Derya Tilki Tags: Review Source Type: research

Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.
Despite the overwhelming evidence for the role of granulocyte colony stimulating factors (G-CSF) in managing febrile neutropenia (FN) risk, chemotherapy-induced neutropenia (CIN) and/or FN still remain the most common reasons for reducing relative dose intensity (RDI) and/or delaying chemotherapy schedule. The need to maintain RDI to ensure optimal clinical outcomes is one of the key rationales for utilizing G-CSF. There is a high incidence of reduced RDI in both curative and palliative settings, and this observation is especially evidenced in retrospective analyses. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - November 10, 2017 Category: Cancer & Oncology Authors: Yassine Lalami, Jean Klastersky Tags: Review Source Type: research

Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: A systematic review
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - November 7, 2017 Category: Cancer & Oncology Authors: Duregon Federica, Vendramin Barbara, Bullo Valentina, Gobbo Stefano, Cugusi Lucia, Di Blasio Andrea, Neunhaeuserer Daniel, Zaccaria Marco, Bergamin Marco, Ermolao Andrea Source Type: research

The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide. It has been reported that left- and right-sided CRC harbor varying disease characteristics, which leads to a difference in prognosis and response to therapy. Recently, there have been retrospective studies about tumor location in metastatic CRC (mCRC) and its potential to predict the effect of anti-vascular endothelial growth factor and anti-epidermal growth factor receptor (anti-EGFR) therapies. In this review, we provide a comprehensive overview of the latest trials studying the predictive value of primary tumor location in mCRC and discus...
Source: Critical Reviews in Oncology Hematology - November 7, 2017 Category: Cancer & Oncology Authors: Nele Boeckx, Katleen Janssens, Guy Van Camp, Marika Rasschaert, Konstantinos Papadimitriou, Marc Peeters, Ken Op de Beeck Tags: Review Source Type: research

The role of Nuclear Factor-kappa B signaling in human cervical cancer
Background The Nuclear Factor kappaB (NF-kB) family consists of transcription factors that play a complex and essential role in the regulation of immune responses and inflammation. NF-kB has recently generated considerable interest as it has been implicated in human cancer initiation, progression and resistance to treatment. In the present comprehensive review the different aspects of NF-kB signaling in the carcinogenesis of cancer of the uterine cervix are discussed. NF-kB functions as part of a network, which determines the pattern of its effects on the expression of several other genes (such as crosstalks with reactive ...
Source: Critical Reviews in Oncology Hematology - November 2, 2017 Category: Cancer & Oncology Authors: Sam Tilborghs, Jerome Corthouts, Yannick Verhoeven, Ron D Arias, Christian Rolfo, Xuan Bich Trinh, Peter A. van Dam Source Type: research

Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma
Targeted therapies are the mainstay of treatment for metastatic renal cell carcinoma (mRCC) (National Comprehensive Cancer Network, 2017). These agents inhibit common molecular pathways that are dysfunctional in mRCC including the vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR) pathways. Food and Drug Administration (FDA)-approved therapies for mRCC that inhibit the VEGF pathway include pazopanib, sunitinib, cabozantinib, lenvatinib, bevacizumab, axitinib, and sorafenib (National Comprehensive Cancer Network, 2017). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - November 1, 2017 Category: Cancer & Oncology Authors: MacKenzie Crist, Elizabeth Hansen, Lipika Chablani, Elizabeth Guancial Tags: Review Source Type: research

ERCC1 As A Prognostic Factor For Survival In Patients With Advanced Urothelial Cancer Treated With Platinum Based Chemotherapy: A Systematic Review And Meta-Analysis
The predictive role of excision repair cross-complementing group 1 (ERCC1) as a predictive factor in patients with advanced urothelial cancer (AUC) treated with platinum-based treatment is not well defined. Here, we evaluate the role of ERCC1 in patients with AUC treated with platinum-based treatment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - November 1, 2017 Category: Cancer & Oncology Authors: Yuksel Urun, Jeffrey J. Leow, Andre P. Fay, Laurence Albiges, Toni K. Choueiri, Joaquim Bellmunt Source Type: research

Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG)
Brainstem gliomas (BSG) account for 15 –20% of all childhood central nervous system (CNS) tumors (Stiller and Nectoux, 1994), and up to 85% of these cases are diffuse intrinsic pontine gliomas (DIPG) (Hargrave et al., 2006). At present, DIPG represents the biggest therapeutic challenge of all BSG subtypes. In addition to occupying crit ical pathways and nuclei, DIPG has a diffuse, infiltrative nature that has given it a reputation of being ‘untouchable’. Radiation is the standard treatment for DIPG; however, despite collaborative efforts to improve treatments, the survival rate of patients with DIPG has remained stat...
Source: Critical Reviews in Oncology Hematology - October 31, 2017 Category: Cancer & Oncology Authors: Ho-Shin Gwak, Hyeon Jin Park Tags: Review Source Type: research

Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: a systematic review
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - October 30, 2017 Category: Cancer & Oncology Authors: Pierluigi Bonomo, Mauro Loi, Isacco Desideri, Emanuela Olmetto, Camilla Delli Paoli, Francesca Terziani, Daniela Greto, Monica Mangoni, Silvia Scoccianti, Gabriele Simontacchi, Giulio Francolini, Icro Meattini, Saverio Caini, Lorenzo Livi Tags: Review Source Type: research

Management of salivary gland malignant tumor: the Policlinico Umberto I, “Sapienza” University of Rome Head and Neck Unit clinical recommendations
Salivary gland malignant tumor (SGMT) is uncommon, accounting less than 5% of all head and neck cancers, and comprises numerous histological entities (Mifsud et al., 2016). The clinicopathologic spectrum ranges from low-grade histologies to high-grade tumors, with important prognosis differences (Terhaard et al., 2004). Nowadays SGMT still represents an assortment of disease states and continues to pose management challenges. Guidelines for SGMT suggest a variety of strategies, reflecting the lack of high-quality evidence demonstrating the superiority of any one approach (National Comprehensive Cancer Network, 2017). (Sour...
Source: Critical Reviews in Oncology Hematology - October 27, 2017 Category: Cancer & Oncology Authors: Francesca De Felice, Marco de Vincentiis, Valentino Valentini, Daniela Musio, Silvia Mezi, Luigi Lo Mele, Marco Della Monaca, Vittorio D ’Aguanno, Valentina Terenzi, Martina Di Brino, Edoardo Brauner, Nadia Bulzonetti, Gianluca Tenore, Giulia Pomati, An Source Type: research

Management of salivary gland malignant tumor: The policlinico Umberto I, sapienza university of rome head and neck unit clinical recommendations
Salivary gland malignant tumor (SGMT) is uncommon, accounting less than 5% of all head and neck cancers, and comprises numerous histological entities (Mifsud et al., 2016). The clinicopathologic spectrum ranges from low-grade histologies to high-grade tumors, with important prognosis differences (Terhaard et al., 2004). Nowadays SGMT still represents an assortment of disease states and continues to pose management challenges. Guidelines for SGMT suggest a variety of strategies, reflecting the lack of high-quality evidence demonstrating the superiority of any one approach (National Comprehensive Cancer Network, 2017). (Sour...
Source: Critical Reviews in Oncology Hematology - October 27, 2017 Category: Cancer & Oncology Authors: Francesca De Felice, Marco de incentiis, Valentino Valentini, Daniela Musio, Silvia Mezi, Luigi Lo Mele, Marco Della Monaca, Vittorio D ’Aguanno, Valentina Terenzi, Martina Di Brino, Edoardo Brauner, Nadia Bulzonetti, Gianluca Tenore, Giulia Pomati, And Source Type: research

Concomitant Use Of Corticosteroids And Immune Checkpoint Inhibitors In Patients With Hematologic Or Solid Neoplasms: A Systematic Review
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - October 27, 2017 Category: Cancer & Oncology Authors: A. Garant, C. Guilbault, T. Ekmekjian, Z. Greenwald, P. Murgoi, T. Vuong Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - October 22, 2017 Category: Cancer & Oncology Source Type: research

Erratum to “Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?” [Crit. Rev. Oncol. Hematol., 119 (November) (2017) 40–49]
The publisher regrets that an incomplete version of Fig. 2 was published. The full version of Fig. 2 is shown below. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - October 19, 2017 Category: Cancer & Oncology Authors: Lotte van der Weijst, Veerle Surmont, Wim Schrauwen, Yolande Lievens Tags: Erratum Source Type: research

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: an indirect comparison of randomized controlled trials
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - October 16, 2017 Category: Cancer & Oncology Authors: Sergio Rizzo, Antonio Galvano, Francesco Pantano, Michele Iuliani, Bruno Vincenzi, Francesco Passiglia, Silvia Spoto, Giuseppe Tonini, Viviana Bazan, Antonio Russo, Daniele Santini Source Type: research